The first demonstration of the utility and safety of UCART occurred in two infants with R/R B-ALL, who achieved CR following CD19 CAR T cells using TALEN gene-editing technology to disrupt the gene encoding for T-cell receptors (TCR) and the gene encoding for CD52 [69]. Here, CD52 is linked to acute lymphoblastic leukemia.